ProCE Banner Activity

ALLIANCE: Phase III Randomized Controlled Trial of BIC/FTC/TAF vs DTG + FTC/TDF in Treatment-Naive Adults With HIV/HBV Coinfection

Slideset Download
Conference Coverage
Significantly greater proportion of patients with HIV/HBV coinfection achieved HBV DNA <29 IU/mL with BIC/FTC/TAF vs DTG + FTC/TDF at 48 weeks; HIV outcomes were similar with both regimens.

Released: August 03, 2022

Expiration: August 02, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Gilead Sciences, Inc.

ViiV Healthcare


IAS 2021

ProCE Banner